Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-PD-1 chimeric antigen receptor T cells efficiently target SIV-infected CD4+ T cells in germinal centers.
Eichholz K, Fukazawa Y, Peterson CW, Haeseleer F, Medina M, Hoffmeister S, Duell DM, Varco-Merth BD, Dross S, Park H, Labriola CS, Axthelm MK, Murnane RD, Smedley JV, Jin L, Gong J, Rust BJ, Fuller DH, Kiem HP, Picker LJ, Okoye AA, Corey L. Eichholz K, et al. Among authors: fuller dh. J Clin Invest. 2024 Apr 1;134(7):e169309. doi: 10.1172/JCI169309. J Clin Invest. 2024. PMID: 38557496 Free PMC article.
Mosaic sarbecovirus vaccination elicits cross-reactive responses in pre-immunized animals.
Cohen AA, Keeffe JR, Schiepers A, Dross SE, Greaney AJ, Rorick AV, Gao H, Gnanapragasam PNP, Fan C, West AP Jr, Ramsingh AI, Erasmus JH, Pata JD, Muramatsu H, Pardi N, Lin PJC, Baxter S, Cruz R, Quintanar-Audelo M, Robb E, Serrano-Amatriain C, Magneschi L, Fotheringham IG, Fuller DH, Victora GD, Bjorkman PJ. Cohen AA, et al. Among authors: fuller dh. bioRxiv [Preprint]. 2024 Feb 9:2024.02.08.576722. doi: 10.1101/2024.02.08.576722. bioRxiv. 2024. PMID: 38370696 Free PMC article. Preprint.
Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina.
Tisoncik-Go J, Voss KM, Lewis TB, Muruato AE, Kuller L, Finn EE, Betancourt D, Wangari S, Ahrens J, Iwayama N, Grant RF, Murnane RD, Edlefsen PT, Fuller DH, Barber GN, Gale M Jr, O'Connor MA. Tisoncik-Go J, et al. Among authors: fuller dh. Front Virol. 2023;3:1108420. doi: 10.3389/fviro.2023.1108420. Epub 2023 Feb 28. Front Virol. 2023. PMID: 37383986 Free PMC article.
Efficient ex vivo expansion of conserved element vaccine-specific CD8+ T-cells from SHIV-infected, ART-suppressed nonhuman primates.
Dross S, Venkataraman R, Patel S, Huang ML, Bollard CM, Rosati M, Pavlakis GN, Felber BK, Bar KJ, Shaw GM, Jerome KR, Mullins JI, Kiem HP, Fuller DH, Peterson CW. Dross S, et al. Among authors: fuller dh. Front Immunol. 2023 May 3;14:1188018. doi: 10.3389/fimmu.2023.1188018. eCollection 2023. Front Immunol. 2023. PMID: 37207227 Free PMC article.
A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned.
O'Connor MA, Hawman DW, Meade-White K, Leventhal S, Song W, Randall S, Archer J, Lewis TB, Brown B, Fredericks MN, Sprouse KR, Tunggal HC, Maughan M, Iwayama N, Ahrens C, Garrison W, Wangari S, Guerriero KA, Hanley P, Lovaglio J, Saturday G, Veesler D, Edlefsen PT, Khandhar AP, Feldmann H, Fuller DH, Erasmus JH. O'Connor MA, et al. Among authors: fuller dh. PLoS Pathog. 2023 Apr 19;19(4):e1011298. doi: 10.1371/journal.ppat.1011298. eCollection 2023 Apr. PLoS Pathog. 2023. PMID: 37075079 Free PMC article.
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice.
Walls AC, VanBlargan LA, Wu K, Choi A, Navarro MJ, Lee D, Avena L, Berrueta DM, Pham MN, Elbashir S, Kraft JC, Miranda MC, Kepl E, Johnson M, Blackstone A, Sprouse K, Fiala B, O'Connor MA, Brunette N, Arunachalam PS, Shirreff L, Rogers K, Carter L, Fuller DH, Villinger F, Pulendran B, Diamond MS, Edwards DK, King NP, Veesler D. Walls AC, et al. Among authors: fuller dh. Cell Rep. 2022 Aug 30;40(9):111299. doi: 10.1016/j.celrep.2022.111299. Epub 2022 Aug 15. Cell Rep. 2022. PMID: 35988541 Free PMC article.
A replicon RNA vaccine induces durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned.
Oâ Connor MA, Hawman DW, Meade-White K, Leventhal S, Song W, Randall S, Archer J, Lewis TB, Brown B, Iwayama N, Ahrens C, Garrison W, Wangari S, Guerriero KA, Hanley P, Lovaglio J, Saturday G, Edlefsen PT, Khandhar A, Feldmann H, Fuller DH, Erasmus JH. Oâ Connor MA, et al. Among authors: fuller dh. bioRxiv [Preprint]. 2022 Aug 9:2022.08.08.503239. doi: 10.1101/2022.08.08.503239. bioRxiv. 2022. PMID: 35982677 Free PMC article. Updated. Preprint.
Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine.
Hawman DW, Meade-White K, Clancy C, Archer J, Hinkley T, Leventhal SS, Rao D, Stamper A, Lewis M, Rosenke R, Krieger K, Randall S, Khandhar AP, Hao L, Hsiang TY, Greninger AL, Gale M Jr, Berglund P, Fuller DH, Rosenke K, Feldmann H, Erasmus JH. Hawman DW, et al. Among authors: fuller dh. EBioMedicine. 2022 Sep;83:104196. doi: 10.1016/j.ebiom.2022.104196. Epub 2022 Aug 4. EBioMedicine. 2022. PMID: 35932641 Free PMC article.
95 results